Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
| CAPS Rating |
|
|---|---|
| Open | $9.47 |
| Previous Close | $9.47 |
| Daily Range | $9.32 - $10.20 |
| 52-Week Range | $3.81 - $12.95 |
| Market Cap | $689.87M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,501,824 |
| Average Daily Volume | 0 |
ACHN
VS S&P 500 (SPY)
How do you think ACHN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ACHN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ACHN News and Commentary
- Has Gilead Sciences Become the Perfect Stock? – The Motley Fool
- Biotech Investors Confident: Industry Sees Big VC Spending in 2011 – The Motley Fool
- Company News for January 25, 2012 - Corporate Summary – NASDAQ
- 5 of Last Week's Biggest Losers – The Motley Fool
- The Week's Biggest Stock Laggards – The Motley Fool
- Optimism and Buyouts Keep Markets Humming – The Motley Fool
- Call me Lucky.. Monster gains in ACHN & IDIX – Blog at The Motley Fool
- 3 Reasons Hep C Premiums Might Not Last – The Motley Fool
- Hepatitis C Drug Developers Shares Soar After Bristol Deal – SmartMoney
- Dance Ballmer, dance! Microsoft is back – CNN Money
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Health Care's Hottest Duo – The Motley Fool
- Ending HIV/AIDS: Hedge Funds Believe in These 5 Companies – The Motley Fool
- Every Biotech Is for Sale – The Motley Fool
- Inhibitex Soars as Investors Chase Hepatitis Drug Developers – Minyanville
- The Biggest Fear for Hep C Investors – The Motley Fool
- Is Achillion Pharmaceuticals the Perfect Stock? – The Motley Fool
- Who's Next on Hep C Biotech Buyout Hit List? – The Motley Fool
- Top Ten Undervalued Stocks With Large Cash Cushions – NASDAQ
RSS Headlines
Fool UK
